An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.
Medscape Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *